124 related articles for article (PubMed ID: 38489974)
1. A prognostic model for SARS-CoV-2 breakthrough infection: Analyzing a prospective cellular immunity cohort.
Yang M; Meng Y; Hao W; Zhang J; Liu J; Wu L; Lin B; Liu Y; Zhang Y; Yu X; Wang X; Gong Y; Ge L; Fan Y; Xie C; Xu Y; Chang Q; Zhang Y; Qin X
Int Immunopharmacol; 2024 Apr; 131():111829. PubMed ID: 38489974
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.
Kared H; Jyssum I; Alirezaylavasani A; Egner IM; The Tran T; Tietze L; Lund KP; Tveter AT; Provan SA; Ørbo H; Haavardsholm EA; Vaage JT; Jørgensen K; Syversen SW; Lund-Johansen F; Goll GL; Munthe LA
Front Immunol; 2024; 15():1296273. PubMed ID: 38455062
[TBL] [Abstract][Full Text] [Related]
3. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
4. Cross-protection induced by highly conserved human B, CD4
Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzer B; Shaik AM; Chilukuri A; Edwards RA; Singer M; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
Front Immunol; 2024; 15():1328905. PubMed ID: 38318166
[TBL] [Abstract][Full Text] [Related]
5. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
6. Immune Response to SARS-CoV-2 Vaccine in 2 Men.
Gupta S; Su H; Agrawal S
Int Arch Allergy Immunol; 2022; 183(3):350-359. PubMed ID: 34794147
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency.
Gupta S; Su H; Narsai T; Agrawal S
Int Arch Allergy Immunol; 2021; 182(3):195-209. PubMed ID: 33486489
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients.
Honfi D; Gémes N; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Toldi G; Puskás LG; Szebeni GJ; Balog A
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232710
[TBL] [Abstract][Full Text] [Related]
10. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
11. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.
Chensue SW; Siler AF; Kim PS; Dimcheff DE; Daghfal DJ; Prostko J; Frias E; Linder KA; Schildhouse RJ
Microbiol Spectr; 2022 Dec; 10(6):e0274722. PubMed ID: 36409132
[TBL] [Abstract][Full Text] [Related]
13. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern.
Ruhl L; Kühne JF; Beushausen K; Keil J; Christoph S; Sauer J; Falk CS
Front Immunol; 2023; 14():1120010. PubMed ID: 37033958
[TBL] [Abstract][Full Text] [Related]
14. Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients.
Seija M; García-Luna J; Rammauro F; Brugnini A; Trías N; Astesiano R; Santiago J; Orihuela N; Zulberti C; Machado D; Recalde C; Yandián F; Guerisoli A; Noboa J; Orihuela S; Curi L; Bugstaller E; Noboa O; Nin M; Bianchi S; Tiscornia A; Lens D
Front Immunol; 2023; 14():1202630. PubMed ID: 37942335
[TBL] [Abstract][Full Text] [Related]
15. Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose.
Mangia A; Serra N; Cocomazzi G; Giambra V; Antinucci S; Maiorana A; Giuliani F; Montomoli E; Cantaloni P; Manenti A; Piazzolla V
Front Public Health; 2022; 10():847384. PubMed ID: 35433614
[TBL] [Abstract][Full Text] [Related]
16. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
[TBL] [Abstract][Full Text] [Related]
17. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.
Pušnik J; Monzon-Posadas WO; Zorn J; Peters K; Baum M; Proksch H; Schlüter CB; Alter G; Menting T; Streeck H
Nat Commun; 2023 Feb; 14(1):572. PubMed ID: 36732523
[TBL] [Abstract][Full Text] [Related]
19. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
[TBL] [Abstract][Full Text] [Related]
20. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
